Related Experiment Video
Updated: Aug 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Demyelination-like syndrome in Crohn's disease after infliximab therapy
1Department of Medicine, University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 1W5. hugfree@shaw.ca
Abstract:
An 18-year-old female patient with Crohn's disease involving the ileum and colon developed ankylosing spondylitis. After treatment of her spondylitis with multiple infliximab infusions, new onset of neurological symptoms developed, accompanied by detection of an abnormal white matter signal change on magnetic resonance imaging examination. Although infliximab treatment was terminated, the neurological symptoms and the magnetic resonance imaging changes persisted. Development of new neuropsychiatric changes in Crohn's disease should be thoroughly evaluated to exclude a concomitant demyelinating process. Infliximab infusions should be terminated if demyelination is suspected.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Clinical Manifestations
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

